Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERYP ERYTECH Pharma	$3.10	$4.66	$0.30 ▼ $1.47	$105.77M	2.69	93,510 shs	N/A
MGTX MeiraGTx	$4.64 -9.9%	$6.34	$3.85 ▼ $8.75	$370.97M	1.3	355,971 shs	1.31 million shs
RGNX REGENXBIO	$8.33 +1.8%	$7.43	$5.04 ▼ $16.85	$417.48M	1.11	863,289 shs	1.19 million shs
SANA Sana Biotechnology	$1.78 -0.8%	$1.89	$1.26 ▼ $9.49	$401.35M	1.75	3.34 million shs	2.75 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERYP ERYTECH Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
MGTX MeiraGTx	-8.36%	-12.27%	-0.96%	-20.03%	+0.19%
RGNX REGENXBIO	+2.63%	+3.28%	+38.88%	+13.61%	-48.03%
SANA Sana Biotechnology	-10.50%	+4.68%	+1.70%	-36.97%	-77.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ERYP ERYTECH Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	4.5585 of 5 stars	3.5	3.0	0.0	4.8	1.6	2.5	1.9
RGNX REGENXBIO	4.1 of 5 stars	3.4	1.0	0.0	4.6	2.5	3.3	0.6
SANA Sana Biotechnology	2.2067 of 5 stars	3.4	0.0	0.0	0.0	2.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERYP ERYTECH Pharma	0.00	N/A	N/A	N/A
MGTX MeiraGTx	3.00	Buy	$24.00	417.24% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	279.65% Upside
SANA Sana Biotechnology	2.86	Moderate Buy	$10.80	506.74% Upside

Current Analyst Ratings Breakdown

Latest ERYP, MGTX, SANA, and RGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	MGTX MeiraGTx	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $35.00
4/24/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
4/17/2025	RGNX REGENXBIO	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00
3/20/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $52.00
3/18/2025	RGNX REGENXBIO	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
3/18/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/18/2025	SANA Sana Biotechnology	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$5.00
3/17/2025	MGTX MeiraGTx	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$11.00 ➝ $13.00
3/17/2025	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
3/14/2025	RGNX REGENXBIO	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$22.00 ➝ $24.00
3/14/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $52.00

(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERYP ERYTECH Pharma	$32.66M	3.24	N/A	N/A	$0.80 per share	3.88
MGTX MeiraGTx	$33.28M	11.15	N/A	N/A	$2.17 per share	2.14
RGNX REGENXBIO	$83.33M	5.01	N/A	N/A	$7.09 per share	1.17
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERYP ERYTECH Pharma	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	-$84.03M	-$2.13	N/A	12.21	0.37	-633.05%	-146.38%	-53.05%	N/A
RGNX REGENXBIO	-$263.49M	-$4.61	N/A	N/A	N/A	-283.19%	-70.65%	-41.68%	5/14/2025 (Estimated)
SANA Sana Biotechnology	-$283.26M	-$0.88	N/A	N/A	N/A	N/A	-84.22%	-44.97%	5/14/2025 (Estimated)

Latest ERYP, MGTX, SANA, and RGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	MGTX MeiraGTx	-$0.38	-$0.51	-$0.13	-$0.51	$4.44 million	$1.93 million
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A
3/17/2025	Q4 2024	SANA Sana Biotechnology	-$0.25	-$0.23	+$0.02	-$0.21	N/A	N/A
3/13/2025	Q4 2024	MGTX MeiraGTx	-$0.48	-$0.50	-$0.02	-$0.50	$1.50 million	$21.39 million
3/13/2025	Q4 2024	RGNX REGENXBIO	-$1.27	-$1.01	+$0.26	-$1.01	$23.70 million	$21.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERYP ERYTECH Pharma	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERYP ERYTECH Pharma	0.32	3.65	3.65
MGTX MeiraGTx	0.86	2.34	2.34
RGNX REGENXBIO	N/A	3.05	3.05
SANA Sana Biotechnology	N/A	4.47	4.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERYP ERYTECH Pharma	1.09%
MGTX MeiraGTx	67.48%
RGNX REGENXBIO	88.08%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
ERYP ERYTECH Pharma	1.94%
MGTX MeiraGTx	7.50%
RGNX REGENXBIO	12.79%
SANA Sana Biotechnology	30.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERYP ERYTECH Pharma	49	34.12 million	33.46 million	Not Optionable
MGTX MeiraGTx	300	79.95 million	71.59 million	Optionable
RGNX REGENXBIO	370	50.12 million	43.04 million	Optionable
SANA Sana Biotechnology	380	225.48 million	153.83 million	Optionable

ERYP, MGTX, SANA, and RGNX Headlines

Recent News About These Companies

Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Before May 20, 2025 - Contact Levi & Korsinsky

May 14 at 3:15 PM | accessnewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology

May 14 at 2:50 PM | globenewswire.com

May 20, 2025 Deadline Approaching: Join Class Action Against Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky

May 14 at 2:15 PM | accessnewswire.com

SANA DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages Sana Biotechnology, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA

May 14 at 1:32 PM | accessnewswire.com

Contact Levi & Korsinsky by May 20, 2025 to Join Class Action Against Sana Biotechnology, Inc. (SANA)

May 14 at 9:45 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA

May 14 at 9:00 AM | accessnewswire.com

Securities Fraud Class Action Filed Against Sana Biotechnology, Inc. (SANA) - Levi & Korsinsky Reminds Investors of May 20, 2025

May 14 at 7:15 AM | accessnewswire.com

SANA Shareholders Have Opportunity to Lead Sana Biotechnology, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!

May 14 at 7:00 AM | accessnewswire.com

Integral Health Asset Management LLC Boosts Stake in Sana Biotechnology, Inc. (NASDAQ:SANA)

May 14 at 6:18 AM | marketbeat.com

Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 – SANA

May 13 at 5:30 PM | accessnewswire.com

SANA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA

May 13 at 5:00 PM | accessnewswire.com

SANA DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA

May 13 at 1:56 PM | markets.businessinsider.com

Shareholders of Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA

May 13 at 1:45 PM | accessnewswire.com

May 20, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SANA

May 13 at 12:30 PM | globenewswire.com

Investors in Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA

May 13 at 9:45 AM | accessnewswire.com

Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA

May 13 at 7:25 AM | accessnewswire.com

SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!

May 13 at 7:00 AM | accessnewswire.com

Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & Korsinsky

May 13 at 5:45 AM | prnewswire.com

Sana Biotechnology (NASDAQ:SANA) Posts Earnings Results, Beats Expectations By $0.02 EPS

May 12 at 11:36 PM | marketbeat.com

Sana Biotechnology, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA

May 12 at 8:15 PM | accessnewswire.com

Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference

May 12 at 4:05 PM | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERYP, MGTX, SANA, and RGNX Company Descriptions

ERYTECH Pharma NASDAQ:ERYP

ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.

MeiraGTx NASDAQ:MGTX

$4.64 -0.51 (-9.90%)

As of 04:00 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

REGENXBIO NASDAQ:RGNX

$8.33 +0.15 (+1.83%)

As of 04:00 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Sana Biotechnology NASDAQ:SANA

$1.78 -0.02 (-0.84%)

As of 04:00 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time